BioCentury
ARTICLE | Company News

Regeneron, bluebird ink multitarget deal for cancer

August 10, 2018 6:14 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human antibodies and TCRs against tumor-specific antigens and bluebird will use its lentiviral vector technology to further develop the therapies.

The five-year deal is Regeneron's second in the cell therapy space and will help bluebird build its oncology pipeline, which currently comprises clinical CAR T therapies bb2121 and bb21217. Both therapies target tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269) to treat multiple myeloma (MM) and are partnered with Celgene Corp. (NASDAQ:CELG)...